Anna Piekarska

Proff

Medical University of Lodz

Poland

Research Interests

Explore related searches

Professors in Poland

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Anna Piekarska is a Professor at the Medical University of Lodz in Poland. Her research focuses on the management of infectious diseases, notably in relation to SARS-CoV-2 and hepatitis C virus infections. Recent publications address clinical practice guidelines, the effectiveness of antiviral therapies, and the impact of COVID-19 on HIV infection profiles. With a commitment to advancing clinical practice, she actively contributes to understanding the complexities of viral infections among diverse patient populations.

Articles (18)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (23)

Rafal Krygier

head

POLAND

Anna Piekarska

Research Interests

Explore related searches

Contact this professor

About

Articles (18)

Management of SARS-CoV-2 Infection-Clinical Practice Guidelines of the Polish Association of Epidemiologists and Infectiologists, for 2025

Response to therapy with direct antiviral drugs in HCV-infected patients with diabetes

Tracking clinical severity of influenza in adult hospitalized patients in 2024: Data from the FluTer registry in Poland

Direct‐acting antivirals in women of reproductive age infected with hepatitis C virus

Treatment of Hepatitis C Virus Infections Among Patients of Ukrainian Origin During the Influx of War Refugees to Poland

Effectiveness of glecaprevir/pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir/emtricitabine/tenofovir alafenamide

Has COVID-19 Changed the Incidence and Profile of Late Presenters for HIV Infection in Lodz, Polish Reference Centre, Poland?

Real-life effectiveness of antiviral therapy for HCV infection with pangenotypic regimens in HIV coinfected patients

Change in the Clinical Picture of Hospitalized Patients with COVID-19 between the Early and Late Period of Dominance of the Omicron SARS-CoV-2 Variant

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens

Assessment of Reactivity to the Administration of the mRNA Vaccine after Six Months of Observation

Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study

The association of airborne particulate matter and benzo[a]pyrene with the clinical course of COVID-19 in patients hospitalized in Poland

Severe Breakthrough COVID-19 Cases during Six Months of Delta Variant (B.1.617.2) Domination in Poland

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study

Effectiveness and safety of pangenotypic regimens in the most difficult to treat population of genotype 3 HCV infected cirrhotics.

COVID-19 impact on perinatal care: risk factors, clinical manifestation and prophylaxis. Polish experts’ opinion for December 2020

Collaborators (23)

Rafal Krygier

Dorota Zarębska-Michaluk

Piotr Czupryna

Krzysztof Kłos

Sebastian Słomka

Justyna Kowalska

Malgorzata Pawlowska

Piotr Rzymski

Katarzyna Sikorska

Robert Flisiak

Krystyna Dobrowolska

Diana Martonik

Ewa Janczewska

Izabela Zaleska

Regina Podlasin

Barbara Sobala-Szczygiel

Krzysztof Simon

Anna Moniuszko-Malinowska

Oskar Rosiak

Marta Rorat

Piotr Stępień

Jerzy Jaroszewicz

Wlodzimierz Mazur

Make your next move.